The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1378
What about Niacin?
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The results of the AIM-HIGH trial conducted by the US National Heart, Lung and Blood Institute (NHLBI) were recently published.1 The goal of the trial was to test whether addition of niacin to intensive statin therapy would further reduce the risk of cardiovascular disease. The trial was stopped prematurely after an average follow-up of 3 years because niacin therapy had not shown any clinical benefit.

NIACIN — Through several mechanisms of action, niacin favorably modifies all plasma lipoproteins and lipids.2 It increases high-density lipoprotein cholesterol (HDL-C) by 15-35% and decreases triglycerides by 20-35%. It decreases total plasma and low-density lipoprotein cholesterol (LDL-C) by 5-25%, changing small, dense LDL particles to large, buoyant forms.3

THE AIM-HIGH TRIAL — A ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: What about Niacin?
Article code: 1378a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian